Genmab ( ) - 株価, ニュースと分析XTRA:GE9

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

GE9 株式概要

Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

会社概要

GE9 ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	4/6
過去の実績	1/6
財務の健全性	6/6
配当金	0/6

報酬

当社が推定した公正価値より63.5%で取引されている

収益は年間28.92%増加すると予測されています

リスク分析

高いレベルの非現金収入

株式の流動性は非常に低い

利益率(26.4%)は昨年より低い(51.7%)

Genmab A/S 競合他社

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€937.6m

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Merck KGaA

XTRA:MRK

€69.8b

価格と性能

の歴代最高値、変動、値下がりまとめGenmab
過去の株価
現在の株価	DKK 331.00
52週高値	DKK 353.50
52週安値	DKK 283.00
ベータ	0.60
11ヶ月の変化	0%
3ヶ月変化	0%
1年変化	n/a
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	4,840.30%

Recent updates

株主還元

	GE9	DE Biotechs	DE 市場
7D	0%	2.6%	4.5%
1Y	n/a	-16.4%	13.4%

業界別リターン: GE9がGerman Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。

リターン対市場: GE9 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。

価格変動

Is GE9's price volatile compared to industry and market?
GE9 volatility
GE9 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

安定した株価: GE9過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のGE9のボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1999	1,309	Jan van de Winkel	www.genmab.com

Genmab A/S 基礎のまとめ

Genmab の収益と売上を時価総額と比較するとどうか。
GE9 基礎統計学
時価総額	€22.80b
収益（TTM）	€319.26m
売上高(TTM)	€1.21b

71.4x

PER（株価収益率

18.8x

P/Sレシオ

GE9 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
GE9 損益計算書（TTM）
収益	DKK 9.02b
売上原価	DKK 0
売上総利益	DKK 9.02b
その他の費用	DKK 6.64b
収益	DKK 2.38b

直近の収益報告

Mar 31, 2022

次回決算日

Aug 10, 2022

一株当たり利益（EPS）	36.38
グロス・マージン	100.00%
純利益率	26.35%
有利子負債／自己資本比率	0%

GE9 の長期的なパフォーマンスは？

過去の実績と比較を見る

This company listing is no longer active

GE9 株式概要

報酬

リスク分析

Genmab A/S 競合他社

XTRA:BIO3

€1.3b

XTRA:FYB

€937.6m

NasdaqGS:HZNP

US$26.6b

XTRA:MRK

€69.8b

価格と性能

最新ニュース

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Recent updates

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

株主還元

価格変動

会社概要

Genmab A/S 基礎のまとめ

71.4x

18.8x

収益と収入